Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Bordignon

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Blood|January 5, 2002
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignanciesPaolo Corradini, Corrado Tarella, Attilio Olivieri, et al.
The Journal of Clinical Investigation|August 3, 2007
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapyAlessandro Aiuti, Barbara Cassani, Grazia Andolfi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumorsVanesa Gregorc, Filippo G De Braud, Tommaso M De Pas, et al.
Nature Medicine|December 29, 2009
Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responsesEduardo J Villablanca, Laura Raccosta, Dan Zhou, et al.
Science Translational Medicine|February 6, 2015
In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cellsLuca Biasco, Serena Scala, Luca Basso Ricci, et al.
European Journal of Radiology|September 25, 2010
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patientsIngrid M E Desar, Carla M L van Herpen, Jack J A van Asten, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2009
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursVanesa Gregorc, Giovanni Citterio, Giordano Vitali, et al.
Blood|September 11, 2013
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myelomaMonica Casucci, Benedetta Nicolis di Robilant, Laura Falcone, et al.
Blood|June 20, 2012
T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantationLuca Vago, Giacomo Oliveira, Attilio Bondanza, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapyArmando Santoro, Lorenza Rimassa, Alberto F Sobrero, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Blood|January 5, 2002
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignanciesPaolo Corradini, Corrado Tarella, Attilio Olivieri, et al.
The Journal of Clinical Investigation|August 3, 2007
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapyAlessandro Aiuti, Barbara Cassani, Grazia Andolfi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumorsVanesa Gregorc, Filippo G De Braud, Tommaso M De Pas, et al.
Nature Medicine|December 29, 2009
Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responsesEduardo J Villablanca, Laura Raccosta, Dan Zhou, et al.
Science Translational Medicine|February 6, 2015
In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cellsLuca Biasco, Serena Scala, Luca Basso Ricci, et al.
European Journal of Radiology|September 25, 2010
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patientsIngrid M E Desar, Carla M L van Herpen, Jack J A van Asten, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2009
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursVanesa Gregorc, Giovanni Citterio, Giordano Vitali, et al.
Blood|September 11, 2013
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myelomaMonica Casucci, Benedetta Nicolis di Robilant, Laura Falcone, et al.
Blood|June 20, 2012
T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantationLuca Vago, Giacomo Oliveira, Attilio Bondanza, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapyArmando Santoro, Lorenza Rimassa, Alberto F Sobrero, et al.
Pageof 10